Previous Retreats
Date and Time: Friday, November 17, 2023 | 12:00 PM – 6:00 PM
In-person Location: Dana-Farber Cancer Institute, Conference Room 306/307, 450 Brookline Ave, Boston, MA 02215
Targeting Cyclin-Dependent Kinases (CDKs) in Breast Cancer
12:00 - 12:30 pm | Lunch and Networking | |
INTRODUCTION | ||
12:30-12:40 pm | Welcome and Introductions | Antonio Giordano, MD and Geoffrey Shapiro, MD, PhD |
12:40 – 1:00 pm | Overview of updated clinical data with FDA-approved agents | Erica Mayer, MD, MPH
|
1:00 - 1:10pm | Q&A | |
MECHANISTIC UNDERSTANDING OF CDK4/6 INHIBITOR RESISTANCE FROM CLINICAL SAMPLES | ||
1:10 – 1:25 pm | Development of a composite genomic signature to predict CDK4/6 inhibitor resistance in diverse patient populations | Seth Wander, MD, PhD |
1:25 - 1:35 pm | Q&A | |
1:35 – 1:50 pm | Translating resistance to CDK4/6i in metastatic breast cancer | Daniel Abravanel, MD, PhD |
1:50 - 2:00 pm | Q&A | |
NEXT GENERATION CDK INHIBITORS IN CLINICAL DEVELOPMENT | ||
2:00 – 2:15 pm | Overview of novel agents targeting CDKs 2, 4 and 6 | Antonio Giordano, MD |
2:15 - 2:25 pm | Q&A | |
2:25 - 2:40 pm | 15 Minute Break | |
NEW PRECLINICAL INSIGHTS | ||
2:40 – 2:55 pm | Shifting kinase gear in resistance to CDK4/6 inhibition | Ioannis Sanidas, PhD |
2:55 - 3:10 pm | Q&A | |
| 3:10 – 3:25 pm | A new first-in-class agent to augment CDK4/6-inhibition | Gerburg Wulf, MD, PhD |
| 3:25 - 3:40 pm | Q&A | |
| 3:40 – 3:55 pm | Reversing CDK6 overexpression to circumvent CDK4/6 inhibitor resistance | Geoffrey Shapiro, MD, PhD |
| 3:55 - 4:10 pm | Q&A | |
| 4:10 - 4:25 pm | CDK7 inhibition in ER+ breast cancer: mechanisms of action and reversal of CDK4/6 inhibitor resistance | Rinath Jeselsohn, MD |
| 4:25 - 4:40 pm | Q&A | |
CDK INHIBITORS AND THE IMMUNE MICROENVIRONMENT | ||
4:40 - 4:55 pm | Cell cycle-independent therapeutic benefits of CDK2 inhibition | Peter Sicinski, PhD |
4:55 - 5:10 pm | Q&A | |
WRAP UP | ||
5:10 – 5:20 pm | Closing Comments | Geoffrey Shapiro, MD, PhD |
5:20 – 6:00 pm | Social Networking Hour | |
The End | ||
Date and Time: Friday, October 28, 2022 | 1:00 PM – 6:00 PM
In-person Location: Dana-Farber Cancer Institute, Conference Room 1620, 450 Brookline Ave, Boston, MA 02215
We have prepared an exciting agenda with lots of time for discussion and networking and we hope that you will join us in person or virtually for this research retreat.
2022 AGENDA
| 1:00-1:05 | Welcome and Introductions | |
| 1:05-1:30 | PDX Program in informing subsequent clinical trials | Drs. Nancy Lin Jean Zhao |
| 1:30-2:25 | ADC resistance | Drs. Leif Ellisen/Aditya Bardia |
| 2:25-2:40 | Break | |
| 2:40-3:35 | Organoids | Dr. Sarah Hill |
| 3:35-3:50 | Break | |
| 3:50-4:45 | Optimization for preclinical models for ER+ Breast Cancer | Dr. Nelly Polyak |
| 4:45-5:00 | Closing Comments | |
| 5:00-6:00 | Social Hour |